Private Equity Cardiology: Top Firms in 2026

Key Facts

• As of 2023, 50 PE-backed platforms control 332 cardiology clinic locations across 22 states, up from one platform with 7 locations in 2019.
• Over 94% of all cardiology acquisitions by PE firms occurred between 2021 and 2023, with 215 clinic sites acquired in 2023 alone.
• Florida leads all states with 80 PE-acquired cardiology sites; Texas follows with 76, and Arizona with 29.
• The dominant deal structure is a platform-and-add-on leveraged buyout, where a lead practice anchors sequential regional acquisitions.
• Platform practices command 13-15x earnings before interest, taxes, depreciation, and amortization (EBITDA); add-on acquisitions typically fetch 12-14x EBITDA.
• Nearly half of all privately owned cardiology practices in the US are now PE-owned, per the 2024 MedAxiom cardiovascular provider survey.
• Nearly 1 in 4 PE-acquired cardiology clinic sites (23%) has been sold in a secondary buyout since 2013.

The Cardiology PE Market: Scale, Drivers, and Geography

Cardiology private equity refers to the acquisition and consolidation of outpatient cardiology practices through leveraged buyout strategies. The market grew from a single platform in 2019 to 50 platforms controlling 332 locations by year-end 2023. That represents 3.9% of the approximately 8,200 cardiology practices tracked by Medicare nationwide.

The 2024 MedAxiom survey covered 5,663 physicians and advanced practice providers across 202 cardiovascular programs. It found that nearly half of all privately owned cardiology practices are now PE-backed. A decade ago, roughly 90% of cardiologists worked in independent practice; today, the majority are employed by hospitals or PE-backed platforms.

Two structural forces triggered this shift. The January 2020 CMS rule added percutaneous coronary interventions (PCIs) and 23 cardiac catheterization CPT codes to Medicare's ambulatory surgery center (ASC) reimbursement list. That single policy change made outpatient cardiology substantially more profitable for platform operators.

Independent physicians then faced a 2% Medicare payment cut in 2023. Hospitals collect higher reimbursement than independent practices for identical services, a gap that site-neutral payment reform has not addressed. Both factors made independent practice financially difficult to sustain.

The sector's fragmentation draws fund managers: approximately 80% of US cardiology groups employ 1-5 physicians. Cardiovascular disease affects nearly half of all US adults, and a projected shortfall of 7,080 cardiologists by 2025 creates durable procedural demand. These factors generate the investment opportunities that general partners (GPs) and their limited partners (LPs) require to underwrite multi-platform consolidation.

PE activity concentrates heavily in Sun Belt states. Florida holds 10.0% of its cardiology clinics under PE ownership (80 of 798 sites); Texas stands at 11.3% (76 of 675). Rhode Island leads all states by penetration rate at 37.1%, with 13 of its 35 cardiology sites acquired. The South as a region shows a PE penetration rate of 4.3%, more than triple the 1.5% rate in the Northeast. PE firms also target wealthy communities disproportionately: clinics in the highest-poverty areas are 39% less likely to be acquired than those in the wealthiest communities.

Cardiology Private Equity: Firm Comparison

The table below covers the most active PE sponsors and PE-backed platforms in outpatient cardiology. AUM figures reflect total firm assets under management where publicly disclosed; individual cardiology fund allocations are not separately reported by these firms.

Webster Equity and Ares Management launched the two largest cardiology platforms in the same year. Together, their portfolio companies control the majority of PE-acquired practices across Arizona, Georgia, Iowa, Kansas, New Jersey, Rhode Island, and South Carolina. Bain Capital's National Cardiovascular Partners established the sector's consolidation template a decade earlier and remains the dominant platform in Arizona.

Top Picks by Investment Strategy

Largest Platform Builder: Webster Equity Partners created CVAUSA, which spans 108 locations across 9 states with 330+ physicians, making it the largest PE-backed cardiology network in the United States.

Most Scaled PE Backer by Total AUM: Ares Management brings approximately $352 billion in assets under management to US Heart & Vascular, which operates 78 acquired locations and 200+ physicians across 5 states.

Growth Equity Leader: Varsity Healthcare Partners used growth equity rather than a control buyout for Partners First Cardiology in Austin, Texas. Its $700 million fund closed above its $650 million hard cap, targeting lower middle-market healthcare services.

Top Mid-Market Platform: Lee Equity Partners deployed its $1.3 billion Fund IV to launch Cardiovascular Logistics in February 2023 through the acquisition of Cardiovascular Institute of the South. The platform has grown to 151 physician partners across 6 states.

Strongest MSO Model: Assured Healthcare Partners, with approximately $1.5 billion in assets under management, backs Heart and Vascular Partners using a managed services organization structure that preserves independent practice ownership rather than acquiring majority stakes.

Pioneer in the Sector: Bain Capital launched National Cardiovascular Partners in 2014, six years before the 2020 CMS rule change that accelerated the buyout wave. It remains the Arizona market leader in PE-backed cardiology.

Most Integrated Capital Structure: Deerfield Management deploys capital across PE, venture capital, and credit, creating flexibility unavailable to pure-buyout sponsors. Its Novocardia platform was merged into CVAUSA in 2023, converting an early position into a stake in the sector's largest network.

Top Cardiology PE Firms and Platforms in Detail

Cardiovascular Associates of America (CVAUSA)

CVAUSA is the sector's definitive consolidator, backed by Webster Equity Partners through a $1.5 billion fund. The platform spans 108 clinic locations across 9 states, with 330+ physicians and 150+ advanced practice providers serving more than 750,000 unique patients annually. Its physician-led governance structure is the key differentiator: a Medical Leadership Board sets national clinical priorities, and physicians retain contractual clinical and operational autonomy.

The Novocardia Care Solutions division operates a multi-state Medicare Advantage value-based care agreement with Humana, proactively managing chronic cardiovascular conditions to reduce avoidable hospitalizations. No competing PE-backed cardiology platform has replicated a payer arrangement of this scope.

US Heart & Vascular

Ares Management's approximately $352 billion in total assets gives US Heart & Vascular a capital runway no competing platform can match. Ares acquired the platform in 2021 and expanded it to 78 locations and 200+ physicians across 5 states. The firm added Rubicon Founders as a co-investor specifically to build value-based care capabilities alongside volume growth.

US Heart & Vascular operates all PE-acquired cardiology practices in Kansas, establishing full regional market control in that state.

National Cardiovascular Partners

Bain Capital's National Cardiovascular Partners built its Arizona market position years before most competitors entered the sector. The firm launched the platform in 2014, five years before the 2020 CMS rule change that drove most subsequent investment. Its concentrated strategy drove PE penetration in Arizona to 17.6% of all cardiology clinics (29 of 165 sites).

Key acquisitions include Arizona Cardiovascular Institute and Cardiovascular Consultants LTD in 2019, followed by the 2020 acquisition of Cardiovascular & Arrhythmia Institute with Azura Vascular Care. That deal expanded the platform into electrophysiology, the cardiology subspecialty with median total compensation of $746,444 in 2023 per MedAxiom data.

Cardiovascular Logistics

Lee Equity Partners took a structurally different approach to building a national cardiology platform. Rather than aggregating small practices through add-on acquisitions, Lee's $1.3 billion Fund IV anchored the platform through the acquisition of Cardiovascular Institute of the South (CIS) in Louisiana, already a large multi-decade independent group. The resulting platform encompasses approximately 2,000 team members and 151 physician partners across Florida, Georgia, Illinois, Louisiana, Mississippi, and New York.

Comvest Credit Partners provided a credit facility supporting further geographic expansion. The spread across both the Southeast and Midwest gives Cardiovascular Logistics a more diversified footprint than any other active cardiology PE platform.

Heart and Vascular Partners

Assured Healthcare Partners, with approximately $1.5 billion in assets under management, built Heart and Vascular Partners (HVP) around a managed services organization model. HVP forms strategic partnerships with independent cardiovascular practices without acquiring majority control, providing administrative, operational, and payer contracting support while physicians retain ownership.

Current partnerships include Cardiovascular Health Clinic in Oklahoma, Advanced Heart Group in Chicago, Colorado Springs Cardiology in Colorado, and St. Louis Heart & Vascular in Missouri. For practices seeking the scale benefits of a PE-backed network without a leveraged buyout, HVP is the most structurally distinct option among active participants.

Partners First Cardiology

When Varsity Healthcare Partners backed Partners First Cardiology in Austin, Texas in November 2020, it chose growth equity over a control acquisition. Varsity's $700 million fund, raised above its $650 million hard cap, specializes in lower middle-market healthcare services.

The growth equity structure lets joining physicians retain equity stakes larger than the 20-30% rollover equity typical in a standard leveraged buyout. Independent cardiologists in Texas seeking outpatient facility development and ancillary service expansion without surrendering a controlling interest have a structurally different option here. The investment thesis at Partners First diverges materially from every full-buyout platform on this list.

Novocardia

Deerfield Management's approach illustrates how hybrid capital structures across PE, venture capital, and credit generate positions unavailable through straightforward buyouts. Deerfield backed Novocardia as a Florida-focused cardiology practice management platform, with First Coast Heart & Vascular as its first acquisition in July 2021.

Deerfield merged Novocardia into CVAUSA in 2023, retaining a board seat and key investor status in the combined entity. The transaction shows how early-platform positions can convert into minority stakes in the sector's dominant consolidator, generating partial liquidity while maintaining exposure to the continuing roll-up.

Key Trends in Cardiology PE Investment

The ASC Reimbursement Catalyst and Ongoing Deal Flow

The 2020 CMS rule change remains the primary investment thesis for most cardiology PE sponsors. By adding PCI reimbursement and 23 cardiac catheterization CPT codes to the Medicare ASC-approved list, CMS created a facility fee revenue stream that did not exist for outpatient cardiology before 2020. PE platforms that develop or acquire ambulatory surgery centers alongside their practice networks capture both the professional fee and the facility fee.

The result is higher EBITDA margins that support the 13-15x valuation multiples platform practices command.

Secondary Buyout Cycles and Uncommitted Capital

A secondary buyout rate of 23% (64 of 278 unique clinic sites from 2013 to 2023) confirms that cardiology platforms already cycle through first and second PE sponsors. Platforms launched in 2021 approach their first exit window by 2026, given typical holding periods of 3-7 years.

Substantial uncommitted capital across active healthcare PE funds means there is ample buyer demand for established platforms reaching the exit stage. Each secondary transaction adds new leverage to the platform, which cardiologists with rollover equity should factor into their long-term ownership calculations.

Value-Based Care as a Payer Strategy

CVAUSA's Medicare Advantage partnership with Humana illustrates where the most sophisticated platforms are building revenue beyond fee-for-service procedure volume. Value-based care contracts pay for outcomes: reduced hospitalizations, better care coordination for heart failure patients, and proactive chronic disease management.

For limited partners evaluating healthcare PE opportunities, platforms with established payer relationships carry lower reimbursement risk than pure fee-for-service volume plays.

Geographic Concentration and Regulatory Scrutiny

PE acquisitions remain concentrated in urban and wealthy communities, with 29 states and DC showing zero activity as of 2023. Rhode Island (37.1% penetration), Nevada (26.4%), and Louisiana (23.6%) have reached levels that attract payer and regulatory attention.

Evidence from comparable specialties shows PE acquisition is consistently associated with higher costs and increased utilization. At least one state has enacted mandatory PE healthcare reporting requirements, and federal researchers have called for systematic monitoring of procedural utilization and outcomes as the cardiology PE market matures.

How to Evaluate Cardiology PE Firms

The first decision a cardiology group must make is whether to position as a platform or an add-on. Platform acquisitions command 13-15x EBITDA, offer greater governance rights, and include dedicated management infrastructure. Add-on acquisitions receive 12-14x EBITDA and subordinate the practice to sponsor-appointed leadership.

Groups with three or more physicians, existing ancillary services such as echocardiography or nuclear imaging, or ambulatory surgery center ownership have the scale to negotiate platform terms.

Physician equity rollover deserves equal scrutiny as the headline EBITDA multiple. Most PE-backed cardiology deals retain 20-30% physician equity in the new platform entity, but liquidation preferences, drag-along rights, and anti-dilution provisions vary materially across sponsors. A sponsor's track record in dermatology, gastroenterology, or ophthalmology reveals how the firm treated physician-owners at the end of prior fund lifecycles.

Clinical autonomy provisions are the non-financial terms most likely to determine long-term satisfaction. Contracts giving the PE sponsor authority over staffing ratios or procedure protocols replicate conditions documented in PE hospital research, where patient experience scores declined after acquisition. Governance structures with a physician-led board holding veto power over clinical decisions represent best practice.

Consulting a healthcare M&A advisor with specific cardiology transaction experience before signing a letter of intent is standard for groups seeking competitive terms.

Which Firm Fits Your Needs?

Cardiologist groups seeking full monetization while maintaining access to multi-state growth infrastructure should prioritize CVAUSA (Webster Equity) and US Heart & Vascular (Ares Management). Both offer physician management roles, established administrative systems, and payer contracting leverage unavailable to smaller independent groups. CVAUSA's physician-led governance model makes it the more attractive option for practices where clinical autonomy is a non-negotiable term.

Independent cardiologists in Texas or elsewhere in the South seeking expansion capital without a full sale should evaluate Partners First Cardiology (Varsity Healthcare Partners) and Heart and Vascular Partners (Assured Healthcare Partners). Varsity's growth equity structure preserves majority physician ownership and targets outpatient facility development rather than rapid leveraged consolidation. Heart and Vascular Partners extends this approach nationally through its MSO model, partnering with practices in Oklahoma, Illinois, Colorado, and Missouri without requiring a controlling stake transfer.

Institutional limited partners constructing healthcare alternatives allocations will find the most transparent fund data among Webster Equity ($1.5 billion fund), Lee Equity ($1.3 billion Fund IV), and Varsity Healthcare Partners ($700 million). Ares Management provides cardiology exposure through its broader PE strategy. Bain Capital's cardiology investments operate within its general healthcare PE program rather than a dedicated sector vehicle.

Methodology

This overview of private equity cardiology draws on peer-reviewed cardiology research (Bartlett, Liu, Wadhera et al., 2024), peer-reviewed health economics research (Singh, Reddy, Whaley, 2024), the MedAxiom 2024 Cardiovascular Provider Compensation and Production Survey, and publicly disclosed fund data, platform announcements, and press releases from active PE sponsors. Firm AUM figures reflect total firm assets under management, not cardiology-specific allocations, as individual sector fund sizes are not publicly reported. All deal statistics reflect acquisitions through the end of 2023. No financial figures were estimated or extrapolated beyond what appears in cited academic publications or sponsor-disclosed sources.